Fenwick & West Represents DexCom in $35M Follow-on Offering

By: Michael A. Brown, Robert A. Freedman

Fenwick & West LLP represented DexCom, Inc. (Nasdaq: DXCM), a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems, in its $35 million follow-on public offering. The San Diego-based company sold 4.025 million shares of its common stock.

The offering closed on January 21, 2010, and Canaccord Adams Inc. acted as the sole bookrunner for the offering.

The Fenwick & West transaction team was led by corporate partner Rob Freedman, and included corporate associates Michael Brown and Rob Ricca.

Established in 1972, Fenwick & West provides comprehensive legal services to technology and life sciences clients of national and international prominence. Fenwick & West is committed to providing innovative, cost-effective and practical legal services that focus on global technology industries and issues. We differentiate ourselves by having a deeper understanding of our clients' technologies, industry environments and business needs than is typically expected of lawyers.

Press Contact:

Rob Freedman
Partner, Corporate Group


Don’t have an account yet?